Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.

Mihai Gheorghiade; Ami N. Shah; Muthiah Vaduganathan; Javed Butler; Robert O. Bonow; Giuseppe M.C. Rosano; Scott Taylor; Stuart Kupfer; Frank Misselwitz; Arjun Sharma; Gregg C. Fonarow

doi:10.1016/j.hfc.2013.05.002

Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.

Mihai Gheorghiade^*, Ami N. Shah, Muthiah Vaduganathan, Javed Butler, Robert O. Bonow, Giuseppe M.C. Rosano, Scott Taylor, Stuart Kupfer, Frank Misselwitz, Arjun Sharma, Gregg C. Fonarow

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

33 Scopus citations

Abstract

Hospitalized heart failure (HHF) is associated with unacceptably high postdischarge mortality and rehospitalization rates. This heterogeneous group of patients, however, is still treated with standard, homogenous therapies that are not preventing their rapid deterioration. The costs associated with HHF have added demands from society, government, and payers to improve outcomes. With coordinated and committed efforts in the development of new therapies, improvements may be seen in outcomes for patients with HHF. This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012.

Original language	English (US)
Pages (from-to)	285-290
Number of pages	6
Journal	Heart Failure Clinics
Volume	9
Issue number	3
DOIs	https://doi.org/10.1016/j.hfc.2013.05.002
State	Published - Jul 2013

Keywords

Heart failure
Hospitalized heart failure
Postdischarge mortality

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2013.05.002

Cite this

Gheorghiade, M., Shah, A. N., Vaduganathan, M., Butler, J., Bonow, R. O., Rosano, G. M. C., Taylor, S., Kupfer, S., Misselwitz, F., Sharma, A., & Fonarow, G. C. (2013). Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives. Heart Failure Clinics, 9(3), 285-290. https://doi.org/10.1016/j.hfc.2013.05.002

@article{bd401e8fe6ad4ea191272ee1931f9023,

title = "Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.",

abstract = "Hospitalized heart failure (HHF) is associated with unacceptably high postdischarge mortality and rehospitalization rates. This heterogeneous group of patients, however, is still treated with standard, homogenous therapies that are not preventing their rapid deterioration. The costs associated with HHF have added demands from society, government, and payers to improve outcomes. With coordinated and committed efforts in the development of new therapies, improvements may be seen in outcomes for patients with HHF. This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012.",

keywords = "Heart failure, Hospitalized heart failure, Postdischarge mortality",

author = "Mihai Gheorghiade and Shah, {Ami N.} and Muthiah Vaduganathan and Javed Butler and Bonow, {Robert O.} and Rosano, {Giuseppe M.C.} and Scott Taylor and Stuart Kupfer and Frank Misselwitz and Arjun Sharma and Fonarow, {Gregg C.}",

year = "2013",

month = jul,

doi = "10.1016/j.hfc.2013.05.002",

language = "English (US)",

volume = "9",

pages = "285--290",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "3",

}

Gheorghiade, M, Shah, AN, Vaduganathan, M, Butler, J, Bonow, RO, Rosano, GMC, Taylor, S, Kupfer, S, Misselwitz, F, Sharma, A & Fonarow, GC 2013, 'Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.', Heart Failure Clinics, vol. 9, no. 3, pp. 285-290. https://doi.org/10.1016/j.hfc.2013.05.002

Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives. / Gheorghiade, Mihai; Shah, Ami N.; Vaduganathan, Muthiah et al.
In: Heart Failure Clinics, Vol. 9, No. 3, 07.2013, p. 285-290.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.

AU - Gheorghiade, Mihai

AU - Shah, Ami N.

AU - Vaduganathan, Muthiah

AU - Butler, Javed

AU - Bonow, Robert O.

AU - Rosano, Giuseppe M.C.

AU - Taylor, Scott

AU - Kupfer, Stuart

AU - Misselwitz, Frank

AU - Sharma, Arjun

AU - Fonarow, Gregg C.

PY - 2013/7

Y1 - 2013/7

N2 - Hospitalized heart failure (HHF) is associated with unacceptably high postdischarge mortality and rehospitalization rates. This heterogeneous group of patients, however, is still treated with standard, homogenous therapies that are not preventing their rapid deterioration. The costs associated with HHF have added demands from society, government, and payers to improve outcomes. With coordinated and committed efforts in the development of new therapies, improvements may be seen in outcomes for patients with HHF. This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012.

AB - Hospitalized heart failure (HHF) is associated with unacceptably high postdischarge mortality and rehospitalization rates. This heterogeneous group of patients, however, is still treated with standard, homogenous therapies that are not preventing their rapid deterioration. The costs associated with HHF have added demands from society, government, and payers to improve outcomes. With coordinated and committed efforts in the development of new therapies, improvements may be seen in outcomes for patients with HHF. This article summarizes concepts in developing therapies for HHF discussed during a multidisciplinary panel at the Heart Failure Society of America's Annual Scientific Meeting, September 2012.

KW - Heart failure

KW - Hospitalized heart failure

KW - Postdischarge mortality

UR - http://www.scopus.com/inward/record.url?scp=84879699020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879699020&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2013.05.002

DO - 10.1016/j.hfc.2013.05.002

M3 - Review article

C2 - 23809415

AN - SCOPUS:84879699020

SN - 1551-7136

VL - 9

SP - 285

EP - 290

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 3

ER -

Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes. Academics', Clinicians', Industry's, Regulators', and Payers' Perspectives.

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this